Three double-blind , randomized , placebo-controlled , phaseI studies evaluated the pharmacokinetics of daclizumab HYP in healthy volunteers following single subcutaneous administration ( @ , @ , or @mg ) , multiple subcutaneous administrations ( @ or @mg biweekly with a @mg loading dose ) , or single intravenous administration ( @ or @mg ) .